A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

Exclusion Criteria

• •Leptomeningeal disease or carcinomatous meningitis
• •Uncontrolled and/or active/symptomatic brain metastases.
• •Significant traumatic injury or major surgical procedure within 4 weeks of first dose of study intervention
• •Known hypersensitivity to any component of study intervention
• •Previous (within 3 years) or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in the respective substudy.
• •Active infection requiring systemic anti-infective therapy within 14 days of first dose of study intervention
• •Known HIV infection
• •Active Hepatitis B virus (HBV) infection
• •Active Hepatitis C virus (HCV) infection;
• •Significant cardiac disorder
• •History of risk factors for torsade de pointes (TdP) (e.g., heart failure, family history of long QT syndrome)
• •Participants with inadequately managed diabetes as assessed by the Investigator
• •Toxicities from prior anticancer therapy, defined as not having resolved to Grade ≤1 or as specified in the respective substudy protocol as per NCI CTCAE v.6.0 with the following exceptions: Alopecia of any grade, Peripheral neuropathy Grade ≤2, Autoimmune endocrine disorders Grade ≤2 managed with stable endocrine replacement therapy
• •History of (non-infectious) pneumonitis/interstitial lung disease (ILD), drug-induced ILD, radiation pneumonitis (unless it has resolved without sequelae without use of steroids), or any evidence of clinically-active pneumonitis/ILD
• •History of the following eye disorders: keratitis, ulcerative keratitis